Phase I Study of Combination Immunochemotherapy in Patients With Advanced Colorectal Carcinoma
OBJECTIVES: I. Define toxicity and the maximum tolerated dose of humanized monoclonal
antibody A33 (MOAB A33) when combined with carmustine, fluorouracil, vincristine, and
streptozocin in patients with advanced colorectal cancer. II. Determine the effect of
chemotherapy on human antihuman antibody response and on the pharmacokinetics of humanized
MOAB A33 in these patients. III. Define the humanized MOAB A33 dose for a phase II study.
OUTLINE: This is a dose escalation study of humanized monoclonal antibody A33 (MOAB A33).
Patients receive humanized MOAB A33 IV once a week for 14 weeks. Chemotherapy begins on day
29 and consists of carmustine IV on days 29-33, fluorouracil IV on days 29-33 and 64-68,
vincristine IV on days 29 and 64, and streptozocin IV every 7 days, beginning on day 29, for
10 doses. Courses repeat every 14 weeks in the absence of disease progression or
unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of humanized MOAB
A33. The maximum tolerated dose is defined as the dose at which no more than 2 of 6 patients
experience dose limiting toxicity.
PROJECTED ACCRUAL: There will be 3-18 patients accrued into this study over 2-9 months.
Primary Purpose: Treatment
Sydney Welt, MD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|